Sec Clinical Research

1. Novartis Pharmaceuticals Corporation $2,797,305 41 payments
2. Organon LLC $1,318,125 131 payments
3. Pfizer Inc. $215,975 53 payments
4. Amgen Inc. $85,561 1 payment
5. GlaxoSmithKline, LLC. $44,535 15 payments
6. Boehringer Ingelheim International GmbH $13,976 45 payments
7. Sun Pharmaceutical Industries Inc. $5,262 20 payments
8. Novo Nordisk AS $3,195 1 payment
9. Moderna TX, Inc. $1,817 4 payments

1. Og-8175A-023 $848,224 110 payments
2. A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono) $565,178 3 payments
3. Og-8175A-023 $469,901 21 payments
4. A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging $434,793 2 payments
5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $394,117 5 payments
6. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $363,652 6 payments
7. A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging in Patients With Chronic Heart Failure With Preserved Ejection Fraction $248,863 1 payment
8. A 24 Week Multicenter Double Blind Placebo Controlled Dose Ranging Study to Investigate the Efficacy and Safety of Oral Qbw251 in COPD Patients on Triple Therapy (Laba/Lama/Ics) $227,513 3 payments
9. A Master Phase 123 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children $213,166 49 payments
10. A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $211,249 1 payment

1. Patient care $1,318,125 131 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.